| Nov 15 |
Syndax wins FDA approval for leukemia drug revumenib
|
| Nov 15 |
Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation
|
| Nov 14 |
Biotech Stock Roundup: NVAX Q3 Results, SNDX Down on AML Data, RNA Surges on Study Data
|
| Nov 13 |
Syndax’s stock sinks by 25% despite AML trial meeting primary endpoint
|
| Nov 13 |
Syndax’s revumenib meets primary results in AML trial
|
| Nov 12 |
Syndax: Fall On NPM1m AML Data Of Revumenib Creates Buy Opportunity
|
| Nov 12 |
Syndax Pharmaceuticals Stock Falls After Data From Mid-Stage Study Of Revumenib In Form Of Blood Cancer
|
| Nov 12 |
Syndax falls after mid-stage data for leukemia drug
|
| Nov 12 |
Syndax Announces Positive Pivotal Topline Results from Relapsed or Refractory mNPM1 AML Cohort in AUGMENT-101 Trial of Revumenib
|
| Nov 8 |
Analysts Are Updating Their Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Estimates After Its Third-Quarter Results
|
